These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
    Author: Shi M, Ma J, Feng M, Liang L, Chen H, Wang T, Xie Z.
    Journal: Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998.
    Abstract:
    MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinical treatments. The majority of known METex14 alterations are typical donor/acceptor splicing or ubiquitination site mutations. Herein, two new METex14 variants were detected in two patients with lung adenocarcinoma by targeted next generation sequencing (NGS). Reverse transcription (RT)-based analysis confirmed that these mutations led to MET exon 14 skipping. Our analysis provided evidence for possible targeted therapy options for patients carrying these MET mutations or similar METex14 analogs.
    [Abstract] [Full Text] [Related] [New Search]